TWM
CATX icon

Trueblood Wealth Management’s Perspective Therapeutics CATX Stock Holding History

Trueblood Wealth Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$413K Sell
99,061
-20,000
-17% -$84.5K 0.16% 165
2025
Q4 		$327K Buy
119,061
+50,000
+72% +$143K 0.13% 190
2025
Q3 		$237K Hold
69,061
– – 0.09% 226
2025
Q2 		$238K Buy
69,061
+46,825
+211% +$124K 0.1% 222
2025
Q1 		$47.4K Hold
22,236
– – 0.02% 234
2024
Q4 		$70.9K Buy
22,236
+6,000
+37% +$49K 0.04% 225
2024
Q3 		$217K Buy
+16,236
New +$216K 0.11% 216

Other funds holding CATX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Trueblood Wealth Management's CATX Position: Q1 2026 in Review

Trueblood Wealth Management reduced its Perspective Therapeutics (CATX) stake by 17% in Q1 2026, selling an estimated $84.5K and leaving 99,061 shares worth $413K. The position accounts for 0.16% of the portfolio, ranked #165.

Trueblood Wealth Management first reported a position in CATX in Q3 2024 and has held it in 7 quarters since. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • Trueblood Wealth Management held 99,061 shares of Perspective Therapeutics worth $413K as of Q1 2026.
  • Trueblood Wealth Management sold 20,000 Perspective Therapeutics shares in Q1 2026, an estimated $84.5K.
  • Perspective Therapeutics made up 0.16% of Trueblood Wealth Management's portfolio in Q1 2026, its #165 holding.
  • Trueblood Wealth Management first reported a position in Perspective Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Trueblood Wealth Management's 13F filing for Q1 2026, filed 21 Apr 2026.